Diabetes, heart failure, and myocardial revascularization: Is there a new message from the ISCHEMIA trial?

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Established indications for myocardial revascularization include stable angina, acute coronary syndromes, reduced left ventricular function, left main stenosis, and severe ischemia.
• The ISCHEMIA trial investigated the role of an invasive strategy versus a conservative approach in patients with stable coronary artery disease and moderate-to-severe ischemia.

Purpose of the Study:

• To evaluate the effectiveness of myocardial revascularization in patients with and without diabetes.
• To assess the impact of the ISCHEMIA trial findings on current revascularization guidelines.

Main Methods:

• Analysis of accepted indications for myocardial revascularization.
• Review of the ISCHEMIA trial's primary and secondary endpoints, including angina symptoms, quality of life, and myocardial infarction rates.
• Examination of treatment effect heterogeneity based on diabetes status.

Main Results:

• No difference in revascularization indications between diabetic and non-diabetic patients.
• The ISCHEMIA trial showed no benefit of an invasive strategy for the primary endpoint but demonstrated significant reductions in angina and improvements in quality of life.
• A significant long-term reduction in spontaneous myocardial infarction was observed, offset by a small increase in peri-interventional myocardial infarction.

Conclusions:

• Myocardial revascularization indications remain consistent regardless of diabetes status.
• While not improving survival for the primary endpoint, an invasive strategy offers significant symptomatic relief and improved quality of life in stable ischemic heart disease.
• The ISCHEMIA trial did not reveal treatment effect heterogeneity concerning diabetes, suggesting similar outcomes for both patient groups.